Tanvex BioPharma (TPE:6541) FCF Margin % : -9,834.58% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Tanvex BioPharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Tanvex BioPharma's Free Cash Flow for the three months ended in Mar. 2024 was NT$-330.15 Mil. Tanvex BioPharma's Revenue for the three months ended in Mar. 2024 was NT$3.36 Mil. Therefore, Tanvex BioPharma's FCF Margin % for the quarter that ended in Mar. 2024 was -9,834.58%.

As of today, Tanvex BioPharma's current FCF Yield % is -22.68%.

The historical rank and industry rank for Tanvex BioPharma's FCF Margin % or its related term are showing as below:

TPE:6541' s FCF Margin % Range Over the Past 10 Years
Min: -618373.33 Med: -16300.44 Max: -2450.94
Current: -4373.94

During the past 11 years, the highest FCF Margin % of Tanvex BioPharma was -2450.94%. The lowest was -618373.33%. And the median was -16300.44%.

TPE:6541's FCF Margin % is ranked worse than
87.16% of 1044 companies
in the Biotechnology industry
Industry Median: -139.2 vs TPE:6541: -4373.94

Tanvex BioPharma FCF Margin % Historical Data

The historical data trend for Tanvex BioPharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tanvex BioPharma FCF Margin % Chart

Tanvex BioPharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-618,373.33

-26,218.41

-6,382.46

-2,450.94

Tanvex BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-1,063.76	-2,357.33	-6,752.14	-4,811.25	-9,834.58

Competitive Comparison of Tanvex BioPharma's FCF Margin %

For the Biotechnology subindustry, Tanvex BioPharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tanvex BioPharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Tanvex BioPharma's FCF Margin % falls into.

Tanvex BioPharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Tanvex BioPharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1505.146	/	61.411
	=	-2,450.94 %

Tanvex BioPharma's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-330.147	/	3.357
	=	-9,834.58 %

Tanvex BioPharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Tanvex BioPharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tanvex BioPharma (TPE:6541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tanvex BioPharma Inc (TPE:6541) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 376, Ren'ai Road, Section 4, 13th Floor-1, Da'an District, Taipei, TWN, 106

Website

https://www.tanvex.com

Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others.

Tanvex BioPharma (TPE:6541) Headlines

No Headlines